Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cortical visual impairment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44294   clinical trials with a EudraCT protocol, of which   7351   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Cortical visual impairment. Displaying page 1 of 1.
    EudraCT Number: 2011-006042-32 Sponsor Protocol Number: GE-067-019 Start Date*: 2012-09-12
    Sponsor Name:GE Healthcare Ltd and its affiliates
    Full Title: A Single-Arm Open-Label Multi-Center Study to Determine the Test-Retest Variability of PET Brain Imaging with Flutemetamol (18F) Injection.
    Medical condition: Subjects with amnestic Mild Cognitive Impairment (aMCI)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10057167 Mental impairment disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002527-21 Sponsor Protocol Number: AMYPAD-01 Start Date*: 2018-05-23
    Sponsor Name:University of Geneva
    Full Title: Multicentre, Open-label, Randomised Study to Assess the Diagnostic Value of Amyloid PET Imaging in Patients with Subjective Cognitive Decline Plus, Mild Cognitive Impairment, or Dementia Where Alzh...
    Medical condition: Alzheimer's disease Mild Cognitive Impairment Subjective Cognitive Decline Plus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003728-64 Sponsor Protocol Number: E2027-G000-201 Start Date*: 2018-12-03
    Sponsor Name:Eisai Ltd
    Full Title: A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies
    Medical condition: Dementia With Lewy Bodies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002855-25 Sponsor Protocol Number: EIP-VX00-745-302 Start Date*: 2015-03-11
    Sponsor Name:EIP Pharma, LLC
    Full Title: A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic ...
    Medical condition: Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-006067-28 Sponsor Protocol Number: CST103/CST107-CLIN-011 Start Date*: 2022-01-10
    Sponsor Name:CuraSen Therapeutics, Inc.
    Full Title: A Phase II, Randomized, Placebo-Controlled, Double-Blind, Crossover, Study of the Pharmacodynamic Effects of CST-103 co-administered with CST-107 on the Central Nervous System in Subjects with Neur...
    Medical condition: Patients with Parkinson’s Disease with REM sleep behaviour disorder, Mild Cognitive Impairment, Dementia with Lewy Bodies and Parkinson’s Disease Dementia.
    Disease: Version SOC Term Classification Code Term Level
    24.0 10029205 - Nervous system disorders 10012284 Dementia due to Parkinson's disease LLT
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    21.1 10029205 - Nervous system disorders 10009846 Cognitive impairment LLT
    20.0 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002145-63 Sponsor Protocol Number: INMiND-02 Start Date*: 2015-10-15
    Sponsor Name:University of Southampton
    Full Title: A double-blind, placebo-controlled study of the effect of a TNF alpha inhibitor, etanercept (Enbrel), on microglial activation in amyloid PET positive patients with Mild Cognitive Impairment due to...
    Medical condition: Mild Cognitive impairment- due to Alzheimer's disease- intermediate likelihood
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013030-25 Sponsor Protocol Number: GE-067-007 Start Date*: 2010-05-12
    Sponsor Name:GE Healthcare Ltd. and its Affiliates
    Full Title: A Principal Open-Label Study to Compare the Brain Uptake of [18F]flutemetamol with Brain Amyloid Levels Determined Post-Mortem
    Medical condition: The subjects have a short life expectancy. GE-067-007 will determine the level of association between brain uptake of (18F)flutemetamol and brain amyloid levels. Assessments will be based on analy...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048669 Terminal state LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000422-38 Sponsor Protocol Number: PET_imaging_of_Tau Start Date*: 2014-09-19
    Sponsor Name:Skåne University Hospital, Region Skåne
    Full Title: An open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau
    Medical condition: Neurodegenerative disorders with Tau-pathology; including Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and important differential diagnost...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    17.0 10029205 - Nervous system disorders 10053643 Neurodegenerative disorder PT
    17.0 10029205 - Nervous system disorders 10009846 Cognitive impairment LLT
    17.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    17.0 10029205 - Nervous system disorders 10012285 Dementia due to Pick's disease LLT
    17.0 10029205 - Nervous system disorders 10012267 Dementia PT
    17.0 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    17.0 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000986-17 Sponsor Protocol Number: ALZ-801-201ADBM Start Date*: 2020-09-11
    Sponsor Name:Alzheon Inc.
    Full Title: A Phase 2, Single Arm, Study of the Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer’s Disease Who Are Carriers of the ε4 Variant of the Apolipoprotein E Gene (APOE4/4 or APOE3/4)
    Medical condition: Subjects with a clinical diagnosis of Alzheimer's disease who are APOE 4 carriers (APOE4/4, APOE3/4) and at the Early stage of disease, ages 50-80 years
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005397-34 Sponsor Protocol Number: Issue1 Start Date*: 2012-02-24
    Sponsor Name:University Hospital Bristol NHS Foundation Trust
    Full Title: Xenon and cooling therapy in babies at high risk of brain injury following poor condition at birth: Randomised pilot study. (CoolXenon2 study)
    Medical condition: Neonatal hypoxia-ischaemia (HI). There is no exact MedDRA term for this. The closest MedDRA terms matching this are neonatal asphyxia and neonatal hypoxia.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10050081 Neonatal hypoxia PT
    14.1 10036585 - Pregnancy, puerperium and perinatal conditions 10028946 Neonatal hypoxia and asphyxia HLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10028923 Neonatal asphyxia PT
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001476-11 Sponsor Protocol Number: AL002-2 Start Date*: 2020-11-12
    Sponsor Name:Alector Inc.
    Full Title: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AL002 IN PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE
    Medical condition: Early Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed) DE (Completed) IT (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002502-74 Sponsor Protocol Number: NEU-01-02-01 Start Date*: 2012-02-14
    Sponsor Name:Neurophyxia B.V.
    Full Title: A multi-centre, randomised, double-blind, placebo-controlled Phase II study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of 2-iminobiotin (2-IB) in neonates with gestational...
    Medical condition: Perinatal asphyxia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10004943 Birth asphyxia LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003500 Asphyxia neonatal LLT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA